<DOC>
	<DOCNO>NCT01032681</DOCNO>
	<brief_summary>Primary trial objective three arm trial ass safety tolerability EMD 521873 , determine whether maximum tolerate dose ( MTD ) reach EMD 521873 dose 1.5 mg/kg give alone combination fix , low-dose cyclophosphamide ( CPA ) patient metastatic locally advanced solid tumor B-cell non-Hodgkin lymphoma . Secondary objective evaluate pharmacokinetic , immunogenicity , overall best clinical response , change tumor marker level , survival biological/immune response EMD 521873 . A total 78 patient plan . Patients remain dose throughout trial . It intend administer 3 cycle ( 21 , progression xxx line therapy become necessary .</brief_summary>
	<brief_title>EMD 521873 Advanced Solid Tumors , MTD Finding</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>1 . Signed write informed consent 2 . Male female , age ≥ 18 year , inpatient treatment phase cycle 1 2 , outpatient treatment possible subsequent cycle 3 . Histologically cytologically proven metastatic locally advanced solid tumor ( epithelial mesenchymal cancer ) Bcell nonHodgkin lymphoma standard therapy exist failure standard therapy 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 study entry estimate life expectancy least 3 month 5 . Adequate hematological function define WBC count ≥ 3 x 109/L absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L lymphocyte count ≥ 0.5 x 109/L ; platelet count ≥100 x 109/L ; hemoglobin ≥9 g/dL ( If laboratory value hemoglobin outside required entry level Screening , patient may receive transfusion RBC . A stable hemoglobin level ≥9 mg/dL least 7 day must achieve prior receive first dose study medication . ) 6 . Adequate hepatic function define total bilirubin level ≤ 1.5 time upper limit normal ( ULN ) aspartateaminotransferase ( AST ) alanineaminotransferase ( ALT ) level ≤ 2.5 x ULN , patient document metastatic disease liver , AST ALT level ≤ 5 x ULN 7 . No history acute chronic kidney disease adequate renal function define estimate creatinine clearance 50 mL/min determine 24hour urine sample CockcroftGault formula 8 . Effective contraception male female subject risk conception exist 1 . Prior IL2 therapy within last 6 month 2 . Requirement concurrent anticancer treatment ( chemotherapy , radiotherapy , immune therapy , cytokine therapy except erythropoietin ) concurrent systemic therapy steroid immunosuppressive agent . Shortterm administration steroid ( i.e . allergic reaction ) allow . 3 . Radiotherapy , chemotherapy , surgery ( exclude prior diagnostic biopsy ) investigational drug 30 day start treatment study 4 . Acquired immune defect human immunodeficiency virus ( HIV ) 5 . Systemic autoimmune disease ( e.g . lupus erythematodes , rheumatoid arthritis , Addison 's disease , autoimmune disease associate lymphoma ) 6 . Organ transplant recipient 7 . History active inflammatory bowel disease ( e.g . Crohn 's disease , ulcerative colitis ) 8 . Chronic viral infection ( e.g . hepatitis B virus [ HBV ] , hepatitis C virus [ HCV ] ) 9 . Uncontrolled hypertension ( systolic &gt; 180 mmHg , diastolic &gt; 100 mmHg ) 10 . Known hypersensitivity reaction compound study medication 11 . Confirmed clinically suspect brain metastasis 12 . Pregnancy ( absence confirm betahuman chorionic gonadotropin [ βHCG ] test ) lactation period 13 . Clinically significant ( i.e . active ) cardiovascular disease : Cerebral vascular accident /stroke ( &lt; 6 month prior enrolment ) , myocardial infarction ( &lt; 6 month prior enrolment ) , unstable angina , congestive heart failure serious cardiac arrhythmia require medication . 14 . Pulmonary disease , opinion investigator , might impair patient 's respiratory tolerance moderate pulmonary fluid overload ( e.g . interstitial lung disease , severe chronic obstructive pulmonary disease ) 15 . All condition associate significant necroses non tumorbearing tissue like e.g . esophageal gastroduodenal ulcer ( &lt; 6 month prior enrolment ) , organ infarction ( &lt; 6 month prior enrolment ) active ischemic bowel disease 16 . Presence medically significant third space fluid ( pericardial effusion ascites/ pleural infusion require repetitive paracentesis ) 17 . Known alcohol drug abuse 18 . Participation another clinical trial within past 30 day start study treatment 19 . All significant disease , opinion investigator , might impair patient 's tolerance study treatment . 20 . Dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>B-Cell Non-Hodgkin Lymphoma</keyword>
	<keyword>Immunocytokine</keyword>
	<keyword>interleukin-2</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>Metastatic Locally Advanced Solid Tumors B-Cell Non-Hodgkin Lymphoma</keyword>
</DOC>